

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended) An isolated biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1, or SEQ ID NO:2, or SEQ ID NO:3, ~~[[and]]~~ or SEQ ID NO:4.

Claims 2-38. (cancelled).

Claim 39. (withdrawn-currently amended) A method for determining the presence of an isolated biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1, or SEQ ID NO:2, or SEQ ID NO:3, ~~[[and]]~~ or SEQ ID NO:4 comprising:

(a) obtaining a sample from a patient;

(b) conducting mass spectrometric analysis on said sample ~~in a manner effective to maximize analysis of~~ to elucidate peptide fragments contained therein and comparing mass spectrum profiles of said isolated biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1, or SEQ ID NO:2, or SEQ ID NO:3, ~~[[and]]~~ or SEQ ID NO:4 to mass spectrum profiles of peptides obtained and analyzed

from said sample; and

©) confirming the presence of said isolated biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1, or SEQ ID NO:2, SEQ ID NO:3, or ~~[[and]]~~ SEQ ID NO:4 in said sample displaying a peak profile ~~selected from the group~~ consisting of 1356.65 daltons for SEQ ID NO:1, 1625.84 daltons for SEQ ID NO:2, 1818.97 daltons for SEQ ID NO:3 and 1629.8713 daltons for SEQ ID NO:4 in said mass spectrum profile;

wherein the presence of said isolated biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1, or SEQ ID NO:2, or SEQ ID NO:3, ~~[[and]]~~ or SEQ ID NO:4 is indicative of a link to Alzheimer's disease.

Claim 40. (withdrawn-previously presented) The method of claim 39, wherein said sample is an unfractionated body fluid or a tissue sample.

Claim 41. (withdrawn-previously presented) The method of claim 39, wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

Claim 42. (withdrawn-currently amended) The method of claim 39, wherein said mass spectrometric analysis is selected from the group of mass spectrometry procedures consisting of Surface Enhanced Laser Desorption Ionization (SELDI) ~~mass spectrometry (MS), Maldi Qq TOF, MS/MS, TOF-TOF, ESI-Q-TOF~~ Matrix-Assisted Laser Desorption/Ionization quadropole quadropole time-of-flight (MALDI Qq TOF), multiple sequential mass spectrometry (MS/MS), sequential time-of-flight (TOF-TOF), electrospray ionization quadropole time-of-flight (ESI-Q-TOF) and ION-TRAP.

Claim 43. (withdrawn-previously presented) The method of claim 39, wherein said patient is a human.

Claim 44. (withdrawn-currently amended) A kit for determining the presence of an isolated biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1, or SEQ ID NO:2, or SEQ ID NO:3, [[and]] or SEQ ID NO:4 comprising: (a) a peptide selected from the group consisting of SEQ ID NO:1; or SEQ ID NO:2, or SEQ ID NO:3 [[and]] or SEQ ID NO:4, and (b) an antibody that binds to said peptide in a sample from a patient.

Claim 45. (previously presented) The kit of claim 44, wherein said antibody is immobilized on a solid support.

Claim 46. (previously presented) The kit of claim 44, wherein said antibody is labeled.